Tagrisso Tablet, Film Coated
Product Images NDC 0310-1350

13 FDA label images from Astrazeneca Pharmaceuticals Lp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Tagrisso (NDC 0310-1350). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chem_structure (Image 01)

Chem_structure (Image 01)
Chemical structure of osimertinib, the active ingredient in TAGRISSO tablets. The diagram shows the molecular framework of osimertinib with key functional groups and bonds represented. This structure is used in the drug's FDA product labeling.*
FDA Label Image

Figure_1 (Image 07)

Figure_1 (Image 07)
A Kaplan-Meier survival curve chart showing the probability of disease-free survival over time (months) from randomization, comparing TAGRISSO and placebo. The chart includes censored data points and a table displaying the number of subjects at risk at various time intervals for both treatment groups.*
FDA Label Image

Figure_2 (Image 02)

Figure_2 (Image 02)
A line graph depicting the probability of overall survival over time (months) comparing TAGRISSO (osimertinib) versus placebo from randomization. The graph includes a table below showing the number of subjects at risk over time for each group, with censored patients marked. The x-axis represents time in months, and the y-axis represents the probability of overall survival.*
FDA Label Image

Figure_3.jpg (Image 03)

Figure_3.jpg (Image 03)
A Kaplan-Meier plot illustrating the probability of progression-free survival over time (months) from randomization, comparing TAGRISSO (osimertinib) with placebo. The plot includes survival curves for each group, a risk table showing the number of patients at risk at different time points, and censored patient markers.*
FDA Label Image

Figure_4 (Figure 4)

Figure_4 (Figure 4)
Kaplan-Meier survival curve comparing the probability of progression-free survival over time (in months) between TAGRISSO (osimertinib) and chemotherapy groups. The graph shows a higher progression-free survival probability for TAGRISSO across the studied period up to 18 months. The number of patients at risk at various time points is displayed below the x-axis.*
FDA Label Image

Figure_5.jpg (Image 04)

Figure_5.jpg (Image 04)
A Kaplan-Meier survival curve graph comparing the probability of overall survival over time in months for patients treated with TAGRISSO versus those treated with EGFR TKI. The solid line represents TAGRISSO and the dashed line represents EGFR TKI, with censored patient data indicated. Patient numbers at risk are listed below the x-axis for both groups across the time intervals.*
FDA Label Image

Figure_6.jpg (Image 05)

Figure_6.jpg (Image 05)
A Kaplan-Meier survival curve chart depicting the probability of progression-free survival over time in months from randomization. It compares two groups: one treated with TAGRISSO plus chemotherapy and the other with TAGRISSO alone. The chart includes censored patient markers and a table below showing the number of subjects at risk at various time points.*
FDA Label Image

Figure_7 (Figure 7)

Figure_7 (Figure 7)
A Kaplan-Meier curve depicting the probability of overall survival over time in months for patients treated with TAGRISSO (osimertinib) alone versus TAGRISSO combined with chemotherapy. The graph includes censored data points and a risk table showing the number of patients at risk at various time points. The chemotherapy regimen is specified as pemetrexed and platinum-based.*
FDA Label Image

Figure_8 (Figure 8)

Figure_8 (Figure 8)
A Kaplan-Meier survival curve comparing the probability of progression-free survival over time (months) between TAGRISSO and chemotherapy groups. The x-axis shows time from randomization in months up to 18 months, and the y-axis shows the probability from 0 to 1. The graph includes a table below indicating the number of patients at risk in each group at various time points and notes censored patients.*
FDA Label Image

Tagrisso_40_mg_tablet_bottle_label (Image 08)

Tagrisso_40_mg_tablet_bottle_label (Image 08)
Label for Tagrisso (osimertinib) tablets, 40 mg strength. The package contains 30 tablets. Manufactured for AstraZeneca Pharmaceuticals LP, the label includes the NDC 0310-1349-30 and features the AstraZeneca logo. The label indicates prescription use only.*
FDA Label Image

Tagrisso 80 mg Tablets Bottle Label (Image 09)

Tagrisso 80 mg Tablets Bottle Label (Image 09)
The packaging label for Tagrisso (osimertinib) tablets shows the 80 mg per tablet strength. It includes the quantity of 30 tablets, with the NDC 0310-1350-30. The label also displays the AstraZeneca logo and notes the manufacturer AstraZeneca Pharmaceuticals LP. The design features a blue and purple themed layout with identification and variable data areas.*
FDA Label Image

40_mg (Image 08)

40_mg (Image 08)
Packaging label for Tagrisso (osimertinib) tablets, 40 mg per tablet, containing 30 film-coated oral tablets. The label includes the AstraZeneca logo and states the product is manufactured for AstraZeneca Pharmaceuticals LP, Wilmington, DE, and produced in Switzerland. It features serialization details, NDC 0310-1248-30, and storage instructions with a warning to keep out of reach of children. The label indicates the product is prescription only (Rx only).*
FDA Label Image

80_mg (Image 09)

80_mg (Image 09)
Label for Tagrisso (osimertinib) tablets, 80 mg per tablet, containing 30 tablets. The label includes the AstraZeneca logo and indicates the product is manufactured by AstraZeneca Pharmaceuticals LP. It has additional information such as NDC 0310-1251-30, storage instructions, and warnings to keep out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.